

Stefania Tommasi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3428360/publications.pdf>

Version: 2024-02-01

153
papers

5,510
citations

126907

33
h-index

98798

67
g-index

156
all docs

156
docs citations

156
times ranked

11759
citing authors

#	ARTICLE	IF	CITATIONS
1	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
2	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	1.6	152
3	Next-generation sequencing: advances and applications in cancer diagnosis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7355-7365.	2.0	142
4	Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β -tubulins. <i>International Journal of Cancer</i> , 2007, 120, 2078-2085.	5.1	132
5	Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. <i>Annals of Oncology</i> , 2005, 16, iv14-iv19.	1.2	127
6	Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 5349-5354.	7.0	119
7	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	12.8	119
8	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. <i>Scientific Reports</i> , 2019, 9, 4099.	3.3	112
9	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	2.9	91
10	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
11	3p Microsatellite Alterations in Exhaled Breath Condensate from Patients with Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 738-744.	5.6	75
12	Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2694-2700.	2.5	73
13	Clinical and pathologic characteristics of <i>BRCA</i> -positive and <i>BRCA</i> -negative male breast cancer patients: results from a collaborative multicenter study in Italy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 411-418.	2.5	73
14	Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. <i>Cancer</i> , 1989, 64, 1922-1927.	4.1	70
15	3p Microsatellite Signature in Exhaled Breath Condensate and Tumor Tissue of Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 337-341.	5.6	69
16	Molecular Pathways and Related Target Therapies in Liver Carcinoma. <i>Current Pharmaceutical Design</i> , 2007, 13, 3279-3287.	1.9	68
17	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , 2016, 17, 400-406.	3.4	67
18	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. <i>Breast Cancer Research</i> , 2007, 9, R59.	5.0	64

#	ARTICLE	IF	CITATIONS
19	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
20	MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. <i>Oncotarget</i> , 2015, 6, 471-483.	1.8	51
21	Unclassified variants in BRCA genes: guidelines for interpretation. <i>Annals of Oncology</i> , 2011, 22, i18-i23.	1.2	50
22	BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 578, 395-405.	1.0	48
23	Genetic alterations in hereditary breast cancer. <i>Annals of Oncology</i> , 2004, 15, i7-i13.	1.2	45
24	Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 157-164.	2.8	42
25	BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 161-167.	2.5	42
26	Exhaled breath condensate biomarkers for lung cancer. <i>Journal of Breath Research</i> , 2019, 13, 044002.	3.0	41
27	Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expression. <i>BMC Bioinformatics</i> , 2012, 13, S9.	2.6	39
28	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
29	Molecular and in silico analysis of BRCA1 and BRCA2 variants. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 644, 64-70.	1.0	36
30	KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 104.	8.6	36
31	Different methylation and MicroRNA expression pattern in male and female familial breast cancer. <i>Journal of Cellular Physiology</i> , 2013, 228, 1264-1269.	4.1	34
32	Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer. <i>European Journal of Human Genetics</i> , 2013, 21, 824-830.	2.8	34
33	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 26.	4.4	34
34	Transition and transversion rate in the evolution of animal mitochondrial DNA. <i>BioSystems</i> , 1986, 19, 273-283.	2.0	33
35	Molecular Profiling of Thin-Prep FNA Samples in Assisting Clinical Management of Non-Small-Cell Lung Cancer. <i>Molecular Biotechnology</i> , 2013, 54, 913-919.	2.4	33
36	Mitochondrial DNA variants and risk of familial breast cancer: An exploratory study. <i>International Journal of Oncology</i> , 2014, 44, 1691-1698.	3.3	33

#	ARTICLE	IF	CITATIONS
37	KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy. <i>Cancers</i> , 2019, 11, 1145.	3.7	33
38	Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 861-868.	2.5	32
39	HOX gene methylation status analysis in patients with hereditary breast cancer. <i>Journal of Human Genetics</i> , 2013, 58, 51-53.	2.3	30
40	Developing optimal input design strategies in cancer systems biology with applications to microfluidic device engineering. <i>BMC Bioinformatics</i> , 2009, 10, S4.	2.6	27
41	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1027-1035.	3.4	27
42	New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2710-2718.	4.1	27
43	Mitochondria and Familial Predisposition to Breast Cancer. <i>Current Genomics</i> , 2013, 14, 195-203.	1.6	27
44	HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast. <i>Cancer Letters</i> , 2005, 222, 75-81.	7.2	25
45	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. <i>European Journal of Cancer</i> , 2015, 51, 2289-2295.	2.8	25
46	Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. <i>Frontiers in Oncology</i> , 2018, 8, 583.	2.8	25
47	Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population. <i>Annals of Oncology</i> , 2004, 15, i48-i54.	1.2	23
48	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. <i>Breast</i> , 2018, 38, 92-97.	2.2	23
49	Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases. <i>Translational Oncology</i> , 2019, 12, 389-395.	3.7	23
50	miRNAs as Key Players in the Management of Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 415.	4.1	23
51	Mutations and polymorphic BRCA variants transmission in breast cancer familial members. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 651-657.	2.5	22
52	DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families. <i>Molecular Biotechnology</i> , 2012, 52, 8-15.	2.4	22
53	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	2.8	22
54	miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. <i>Oncotarget</i> , 2016, 7, 80363-80372.	1.8	21

#	ARTICLE	IF	CITATIONS
55	SELDI-TOF serum proteomics and breast cancer: which perspective?. Expert Review of Proteomics, 2008, 5, 779-785.	3.0	20
56	Oncosuppressor methylation: A possible key role in colon metastatic progression. Journal of Cellular Physiology, 2011, 226, 1934-1939.	4.1	20
57	Standardization of CTC AR&V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. Prostate, 2019, 79, 54-61.	2.3	20
58	The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma. Cancers, 2019, 11, 1559.	3.7	20
59	TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget, 2017, 8, 50715-50723.	1.8	20
60	Correlation between ERICA and DCC Assay in Hormone Receptor Assessment of Human Breast Cancer. Oncology, 1988, 45, 308-312.	1.9	19
61	Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Letters, 2004, 209, 215-222.	7.2	19
62	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Biology of Blood and Marrow Transplantation, 2018, 24, 608-613.	2.0	19
63	Breast and Prostate Cancer Risks for Male<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
64	Angiogenesis in adenosquamous cancer of pancreas. Oncotarget, 2017, 8, 95773-95779.	1.8	19
65	Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma. International Journal of Molecular Sciences, 2020, 21, 5243.	4.1	18
66	Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death and Disease, 2014, 5, e1076-e1076.	6.3	17
67	ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. International Journal of Molecular Medicine, 2003, 12, 131-4.	4.0	17
68	Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer. Breast Cancer Research and Treatment, 1988, 11, 31-36.	2.5	16
69	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. Oncology, 2009, 77, 69-74.	1.9	16
70	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell'€Italia Meridionale Multicenter Phase II Study. Oncology, 2010, 79, 415-422.	1.9	16
71	MicroRNA expression profiling in male and female familial breast cancer. British Journal of Cancer, 2014, 111, 2361-2368.	6.4	16
72	miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. Tumor Biology, 2016, 37, 5503-5513.	1.8	16

#	ARTICLE	IF	CITATIONS
73	Gene Copy Number Variation in Male Breast Cancer by aCGH. <i>Analytical Cellular Pathology</i> , 2010, 33, 113-119.	1.4	15
74	Update on capecitabine alone and in combination regimens in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2010, 36, S46-S55.	7.7	15
75	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. <i>PLoS ONE</i> , 2014, 9, e112025.	2.5	15
76	The value of new high-throughput technologies for diagnosis and prognosis in solid tumors. <i>Cancer Biomarkers</i> , 2014, 14, 103-117.	1.7	15
77	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 453-461.	3.4	15
78	Exhaled breath condensate is not suitable to detect EGFR somatic mutations. <i>European Respiratory Journal</i> , 2008, 32, 1126-1127.	6.7	14
79	Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women. <i>European Journal of Cancer Care</i> , 2010, 19, 360-368.	1.5	14
80	Human epidermal growth factor receptor 2, Na ⁺ /H ⁺ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. <i>Human Pathology</i> , 2011, 42, 1589-1595.	2.0	14
81	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). <i>BMC Cancer</i> , 2018, 18, 552.	2.6	14
82	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. <i>Gynecologic Oncology</i> , 2020, 156, 377-386.	1.4	14
83	655Val and 1170Pro ERBB2 SNPs in Familial Breast Cancer Risk and BRCA1 Alterations. <i>Analytical Cellular Pathology</i> , 2007, 29, 241-248.	1.4	14
84	Body Mass Index and Serum Proteomic Profile in Breast Cancer and Healthy Women: A Prospective Study. <i>PLoS ONE</i> , 2012, 7, e49631.	2.5	14
85	β ² -catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2016, 7, 67841-67850.	1.8	14
86	Detection of novel transcripts in the human mitochondrial DNA region coding for ATPase8-ATPase6 subunits. <i>FEBS Letters</i> , 1994, 344, 10-14.	2.8	13
87	Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. <i>Clinical Breast Cancer</i> , 2021, 21, e168-e176.	2.4	13
88	Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?. <i>Clinical Cancer Research</i> , 2007, 13, 5988-5990.	7.0	12
89	Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. <i>Cancer Genetics and Cytogenetics</i> , 2008, 182, 75-83.	1.0	12
90	Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 1356-1365.	2.4	12

#	ARTICLE	IF	CITATIONS
91	Gene copy number variation in male breast cancer by aCGH. Cellular Oncology (Dordrecht), 2011, 34, 467-473.	4.4	12
92	Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report. Breast Cancer Research and Treatment, 2010, 124, 875-878.	2.5	11
93	BRCA1 diagnostic workflow from next-generation sequencing technologies to variant identification and final report. Genes Chromosomes and Cancer, 2016, 55, 803-813.	2.8	11
94	Combination of 5-Fluorouracil and Irinotecan on Modulation of Thymidylate Synthase and Topoisomerase I Expression and Cell Cycle Regulation in Human Colon Cancer LoVo Cells: Clinical Relevance. Clinical Colorectal Cancer, 2002, 2, 182-188.	2.3	10
95	KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. Expert Opinion on Biological Therapy, 2009, 9, 565-577.	3.1	10
96	MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. European Journal of Pharmacology, 2011, 670, 74-84.	3.5	10
97	VEGF and TWIST1 in a 16 biomarker immunoprofile useful for prognosis of breast cancer patients. International Journal of Cancer, 2017, 141, 1901-1911.	5.1	10
98	Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. Journal of Translational Medicine, 2014, 12, 319.	4.4	9
99	Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. Cancer Chemotherapy and Pharmacology, 2015, 76, 433-438.	2.3	9
100	H pylori status and angiogenesis factors in human gastric carcinoma. World Journal of Gastroenterology, 2006, 12, 5465.	3.3	9
101	Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. Genes Chromosomes and Cancer, 2006, 45, 983-994.	2.8	8
102	Synchronous Presentation of B-Cell Chronic Lymphocytic Leukemia/Small-Cell Lymphoma and Colon Adenocarcinoma Within the Same Mesenteric Lymph Nodes and a Single Liver Metastasis. Journal of Clinical Oncology, 2011, 29, e11-e13.	1.6	8
103	Proteomic profile in familial breast cancer patients. Clinical Biochemistry, 2013, 46, 259-265.	1.9	8
104	SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?. Journal of Cellular and Molecular Medicine, 2013, 17, 605-607.	3.6	8
105	BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer. Oncology Reports, 2014, 31, 365-369.	2.6	8
106	Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell and Melanoma Research, 2016, 29, 679-687.	3.3	8
107	Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a caucasian family. Oncotarget, 2017, 8, 29751-29759.	1.8	8
108	Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2. Journal of Translational Medicine, 2019, 17, 20.	4.4	8

#	ARTICLE	IF	CITATIONS
109	Somatic alterations of targetable oncogenes are frequently observed in <i>BRCA1/2</i> mutation negative male breast cancers. <i>Oncotarget</i> , 2016, 7, 74097-74106.	1.8	8
110	Sequential Alternate Administration of Tamoxifen and Medroxyprogesterone Acetate in Advanced Breast Cancer: Clinical-Biological Randomized Study. <i>Tumori</i> , 1990, 76, 190-195.	1.1	7
111	ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. <i>International Journal of Molecular Medicine</i> , 2003, 12, 131.	4.0	7
112	Targeting EGFR in bilio-pancreatic and liver carcinoma. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 16-22.	2.1	7
113	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
114	The Role of Circulating Adiponectin and SNP276G>T at <i>ADIPOQ</i> Gene in <i>BRCA</i> -mutant Women. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 301-307.	2.0	7
115	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1973.	3.0	7
116	<i>NR1H3</i> (LXR β) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 864-875.	1.7	7
117	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. <i>Oncotarget</i> , 2016, 7, 25135-25149.	1.8	6
118	EMSY copy number variation in male breast cancers characterized for <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 181-186.	2.5	6
119	Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7693.	4.1	6
120	Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. <i>Oncology Reports</i> , 2010, 23, 1641-5.	2.6	5
121	Adipokines in hereditary breast cancer patients and healthy relatives. <i>Oncotarget</i> , 2017, 8, 101255-101261.	1.8	5
122	Immunoprofile from tissue microarrays to stratify familial breast cancer patients. <i>Oncotarget</i> , 2015, 6, 27865-27879.	1.8	5
123	Comparison of Data-Merging Methods with SVM Attribute Selection and Classification in Breast Cancer Gene Expression. <i>Lecture Notes in Computer Science</i> , 2012, , 498-507.	1.3	5
124	Therapeutic efficacy of various dosages and modalities of administration. <i>Inorganica Chimica Acta</i> , 1987, 137, 91-97.	2.4	4
125	Mutations spanning P53 exons 5-9 detected by non-isotopic RNase cleavage assay and protein expression in human colon cancer. <i>Cancer Genetics and Cytogenetics</i> , 2001, 129, 40-42.	1.0	4
126	Disease family history and modification of breast cancer risk in common <i>BRCA2</i> variants. <i>Oncology Reports</i> , 0, , .	2.6	4

#	ARTICLE	IF	CITATIONS
127	Genetic risk transmission in a family affected by familial breast cancer. <i>Journal of Human Genetics</i> , 2014, 59, 51-53.	2.3	4
128	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , 2019, 11, 749.	3.7	4
129	A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 847.	2.5	4
130	Induction of fuzzy rules with artificial immune systems in acgh based er status breast cancer characterization. , 2007, , .		3
131	Identification of Tumor Evolution Patterns by Means of Inductive Logic Programming. <i>Genomics, Proteomics and Bioinformatics</i> , 2008, 6, 91-97.	6.9	3
132	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. <i>International Journal of Molecular Medicine</i> , 2008, 21, 809-17.	4.0	3
133	Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test. <i>Diagnostics</i> , 2021, 11, 975.	2.6	3
134	Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing. <i>Cancers</i> , 2021, 13, 4714.	3.7	3
135	Fuzzy Rule Induction and Artificial Immune Systems in Female Breast Cancer Familiarity Profiling. , 2007, , 830-837.		3
136	A Promising Role of TGF- β 2 Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1241.	2.0	3
137	Innovative technology for cancer risk analysis. <i>Annals of Oncology</i> , 2011, 22, i37-i43.	1.2	2
138	The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	2
139	BRCA1/2 Variants and Metabolic Factors: Results From a Cohort of Italian Female Carriers. <i>Cancers</i> , 2020, 12, 3584.	3.7	2
140	Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. <i>Frontiers in Oncology</i> , 2020, 10, 1292.	2.8	2
141	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2227.	4.1	2
142	Artificial Immune Systems in Bioinformatics. <i>Studies in Computational Intelligence</i> , 2008, , 271-295.	0.9	2
143	Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. <i>Diagnostics</i> , 2022, 12, 682.	2.6	2
144	The Impact of Mediterranean Dietary Intervention on Metabolic and Hormonal Parameters According to BRCA1/2 Variant Type. <i>Frontiers in Genetics</i> , 2022, 13, 820878.	2.3	2

#	ARTICLE	IF	CITATIONS
145	Hormone receptor modulation by a sequential alternate TAM/MPA administration monitored by drugs plasma level. Pharmacological Research, 1990, 22, 107-108.	7.1	1
146	Sequencing-grade screening for BRCA1 variants by oligo-arrays. Journal of Translational Medicine, 2008, 6, 64.	4.4	1
147	Determining and Interpreting New Predictive Rules for Breast Cancer Familial Inheritance. OMICS A Journal of Integrative Biology, 2011, 15, 125-131.	2.0	1
148	BRCA Unclassified Variants: How Can They be Classified?. Current Women's Health Reviews, 2012, 8, 30-37.	0.2	1
149	Fluorescence in situ hybridization analysis of HER-2/neu in brushings of normal oral mucosa. Cancer Genetics and Cytogenetics, 2002, 132, 141-144.	1.0	0
150	Correction: Article on Phosphatidylinositol 3-Kinase in Breast Cancer. Clinical Cancer Research, 2008, 14, 1281-1281.	7.0	0
151	Meeting Report: Hereditary Breast and Ovarian Cancer (HBOC): Risks and Challenges. September 10-12, 2009 Bari, Italy. Breast Care, 2009, 4, 347-348.	1.4	0
152	microRNAs and next generation sequencing for the prognosis of the metastatic melanoma. Journal of Translational Medicine, 2015, 13, P4.	4.4	0
153	High-Throughput Analysis of the Drug Mode of Action of PB28, MC18 and MC70, Three Cyclohexylpiperazine Derivative New Molecules. Lecture Notes in Computer Science, 2008, , 1085-1092.	1.3	0